Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
17 hedge funds and large institutions have $22.2M invested in Soleno Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
89% more funds holding
Funds holding: 9 → 17 (+8)
35% more capital invested
Capital invested by funds: $16.4M → $22.2M (+$5.77M)
0.06% more ownership
Funds ownership: 3.14% → 3.2% (+0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$638K |
| 2 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
+$253K |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$97.7K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$86.7K |
| 5 |
KC
Kepos Capital
New York
|
+$73.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$258K |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$215K |
SLNO Hedge Fund Activity: Q2 2018 in Review
17 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2018, worth a combined $22.2M — up 35% from $16.4M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SLNO positions and 1 closed out — a net gain of 8 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Vivo Capital, adding an estimated $638K. The largest seller was Sabby Management, cutting an estimated $258K.
- 17 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2018, up from 9 in Q1 2018.
- Funds reported $22.2M of Soleno Therapeutics stock for Q2 2018, up 35% quarter-over-quarter.
- 9 funds opened new Soleno Therapeutics positions in Q2 2018 and 1 closed out, a net change of +8 holders.
- The largest Soleno Therapeutics buyer in Q2 2018 was Vivo Capital, an estimated $638K added.
- The largest Soleno Therapeutics seller in Q2 2018 was Sabby Management, an estimated $258K sold.
Based on aggregated 13F filings for Q2 2018.